<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Food protein-induced enterocolitis syndrome (FPIES) oral food challenge</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Food protein-induced enterocolitis syndrome (FPIES) oral food challenge</h1>
<div class="graphic"><div class="figure"><div class="ttl">Food protein-induced enterocolitis syndrome (FPIES) oral food challenge</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Protocol</td> </tr> <tr class="divider_bottom"> <td> <ul class="decimal_heading"> <li>Basic requirements – Clinician supervision, secure IV access, immediate availability of fluid resuscitation. </li> <li>Baseline vital signs and complete blood count with differential to determine the baseline peripheral blood neutrophil count. </li> <li>Administration of food protein 0.03 to 0.6 g/kg body weight in 3 equal doses over 45 minutes generally not to exceed total 3 g protein or 10 g of total food (100 mL of liquid) for an initial feeding. A lower dose is used in patients with a history of severe reactions. </li> <li>Observe patients for at least 4 hours from the beginning of the OFC. </li> <li>Very-low-dose initial feeding – If no reaction occurs within 2 to 3 hours of administration of the final dose, feed the patient an age-appropriate serving of the food followed by 4 hours of observation. </li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Criteria for a positive challenge</td> </tr> <tr> <td class="indent1"><strong>Major criterion:</strong> <ul class="decimal_heading"> <li>Vomiting in the 1- to 4-hour period after ingestion of the suspect food and the absence of classic IgE-mediated allergic skin or respiratory symptoms. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>Minor criteria:</strong> <ul class="decimal_heading"> <li>Lethargy. </li> <li>Pallor. </li> <li>Diarrhea in 5 to 10 hours after food ingestion. </li> <li>Hypotension. </li> <li>Hypothermia. </li> <li>Increased neutrophil count of at least 1500 neutrophils above the baseline count*. </li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Interpretation of the food challenge outcome</td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>The OFC is considered diagnostic of FPIES (ie, positive) if the major criterion is met with at least 2 minor criteria.</strong> However, we suggest 2 important caveats to these criteria: <ul class="decimal_heading"> <li>With the rapid use of ondansetron, many of the minor criteria, such as repetitive vomiting, pallor and lethargy, may be averted. </li> <li>Not all facilities performing challenges have the ability to perform neutrophil counts in a timely manner. Therefore, the treating clinician may decide that a challenge is diagnostic in some instances even if only the major criterion was met. </li> </ul> However, in challenges performed for research purposes, adherence to stringent criteria for challenge positivity is the standard.</td> </tr> <tr> <td class="subtitle1_left">Treatment for a positive challenge<sup>¶</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>First-line therapy – Fluid resuscitation with 20 mL/kg IV boluses of normal saline (0.9% sodium chloride). </li> <li>Antiemetic – Ondansetron 0.15 mg/kg<strong> IV</strong>, maximum <strong>single</strong> dose 16 mg. Ondansetron may also be used IM; maximum dose suitable for <strong>IM</strong> administration is 4 mg for ages 12 years and older and 2 mg for younger ages due to the large volume of the injection. </li> <li>Additional therapy for severe reactions – Glucocorticoid (eg, methylprednisolone 1 mg/kg IV, maximum <strong>single</strong> dose 80 mg). </li> <li>Therapy for severe hypotension/shock – IM epinephrine: <ul> <li>Either: <ul> <li><strong>1 mg/mL</strong> ampule: <ul> <li>0.01 mg/kg per dose; maximum single dose 0.3 mL (0.3 mg) for a child &lt;13 years and 0.5 mL (0.5 mg) if ≥13 years. </li> </ul> </li> <li style="list-style-type: none;">OR </li> <li>Auto-injector: <ul> <li>&lt;10 kg – 0.1 mg (infant autoinjector). </li> <li>10 to 25 kg – 0.15 mg IM (pediatric auto-injector). </li> <li>&gt;25 kg – 0.3 mg IM. </li> </ul> </li> </ul> </li> <li>May repeat IM epinephrine after 5 to 15 minutes if needed. </li> <li>IM epinephrine should not be used as a first-line for managing acute FPIES reactions without fluid replacement and antiemetic therapy. </li> <li>In severe shock, IV vasopressors may be needed. </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">OFC for FPIES is considered a high-risk procedure. It should be conducted in a setting where IV access can be secured, rapid fluid resuscitation can be given if a reaction occurs, and prolonged observation can occur, if necessary.</div><div class="graphic_footnotes">FPIES: food protein-induced enterocolitis syndrome; IV: intravenous; OFC: oral food challenge; IgE: immunoglobulin E; IM intramuscular.<br/>	

	* Recommended in the OFC done for research; may also be obtained in the OFC done for clinical indications, as per the clinician discretion.<br/>	

	¶ Treatment is initiated in patients with severe, repetitive emesis; significant tachycardia; hypotension; and/or dusky appearance.</div><div id="graphicVersion">Graphic 87566 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
